The Role of Panretinal Photocoagulation in Neovascular Glaucoma Associated with Central Retinal Vein Occlusion

1991 ◽  
pp. 80-85
Author(s):  
S. S. Hayreh
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Neovascular Glaucoma ◽  
Panretinal Photocoagulation ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals ROLE OF BEVACIZUMAB FOR PREVENTION OF NEOVASCULAR GLAUCOMA IN ACUTE RETINAL VEIN OCCLUSION

2018 ◽  
Vol 9 (1) ◽  
pp. 64-67
Author(s):  
Bassam Mubarik ◽  
Adeen Akram
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Neovascular Glaucoma ◽  
Ischemic Group ◽  
Vein Occlusion ◽  
Group 2 ◽  
Central Retinal Vein

ABSTRACT:There is a possibility of developing neovascular glaucoma in ischemic type of retinal vein occlusion. Purpose of the study is to determine the role of anti VEGF agent bevacizumab for prevention of neovascular glaucoma in ischemic type of retinal vein occlusion.METHOD: It was a retrospective study of 34 cases with unilateral central retinal vein occlusion. All of them were treated with intra vitreous Bevacizumab for management of associated macular edema. Primary outcome was to study development of neovascular glaucoma in these cases.RESULTS: Thirty four cases were selected with retinal vein occlusion. Seventeen cases were of non ischemic type and remaining 17 were of ischemic type vein occlusion. During a follow up period of two years non ischemic group was given on average 8 bevacizumab injection. Only one of these non ischemic eyes developed neo vessels of optic disc but neo vascular glaucoma did not develop. In case of ischemic group during follow up period of two years a mean of 6 bevacizumab injections were given. In this ischemic group 2 cases developed iris neovesseles and 3 cases developed retinal neovesseles. Out of these, three eyes progressed to neovascular glaucoma.CONCLUSION: Bevacizumab treatment of macular edema for ischemic central retinal vein occlusion does not prevent neovascular glaucoma.

scholarly journals Cytokines and Pathogenesis of Central Retinal Vein Occlusion

2020 ◽  
Vol 9 (11) ◽  
pp. 3457
Author(s):  
Hidetaka Noma ◽  
Kanako Yasuda ◽  
Masahiko Shimura
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Neovascular Glaucoma ◽  
Retinal Blood Flow ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) causes macular edema and subsequent vision loss and is common in people with diseases such as arteriosclerosis and hypertension. Various treatments for CRVO-associated macular edema have been trialed, including laser photocoagulation, with unsatisfactory results. However, when the important pathogenic role of vascular endothelial growth factor (VEGF) in macular edema was identified, the treatment of CRVO was revolutionized by anti-VEGF therapy. However, despite the success of intraocular injection of anti-VEGF agents in many patients with CRVO, some patients continue to suffer from refractory or recurring edema. In addition, the expression of inflammatory cytokines increases over time, causing more severe inflammation and a condition that is increasingly resistant to anti-VEGF therapy. This indicates that the pathogenesis of macular edema in CRVO is more complex than originally thought and may involve factors or cytokines associated with inflammation and ischemia other than VEGF. CRVO is also associated with leukocyte abnormalities and a gradual reduction in retinal blood flow velocity, which increase the likelihood of it developing from the nonischemic type into the more severe ischemic type; in turn, this results in excessive VEGF expression and subsequent neovascular glaucoma. Here, we review the role of different factors and cytokines involved in CRVO pathogenesis and propose a mechanism that holds promise for the development of novel therapies.

scholarly journals The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina L. Ryu ◽  
Adrian Elfersy ◽  
Uday Desai ◽  
Thomas Hessburg ◽  
Paul Edwards ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Significant Risk ◽  
Case Series ◽  
Neovascular Glaucoma ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Sign in / Sign up

Export Citation Format

Share Document